IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer

被引：52
|
作者：
Emens, L. A. [1 ]
Adams, S. [2 ]
Barrios, C. H. [3 ]
Dieras, V. C. [4 ]
Iwata, H. [5 ]
Loi, S. [6 ]
Rugo, H. S. [7 ]
Schneeweiss, A. [8 ]
Winer, E. P. [9 ]
Patel, S. [10 ]
Henschel, V. [11 ]
Swat, A. [12 ]
Kaul, M. [13 ]
Molinero, L. [14 ]
Chui, S. Y. [15 ]
Schmid, P. [16 ]
机构：
[1] UPMC Hillman Canc Ctr, Dept Med Hematol Oncol, Pittsburgh, PA USA
[2] NYU, Langone Med Ctr, Sch Med, New York, NY USA
[3] Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Invest Ctr, Porto Alegre, RS, Brazil
[4] Ctr Eugene Marquis, Med Oncol, Rennes, France
[5] Aichi Canc Ctr Hosp, Breast Oncol, Nagoya, Aichi, Japan
[6] Peter MacCallum Canc Ctr, Div Res, Translat Breast Canc Genom Lab, Melbourne, Vic, Australia
[7] UCSF, Helen Diller Family Comprehens Canc Ctr, Breast Dept, San Francisco, CA USA
[8] Univ Hosp Heidelberg, German Canc Res Ctr, Heidelberg, Germany
[9] Dana Farber Canc Inst, Med, Boston, MA 02115 USA
[10] Genentech Inc, Med Oncol, San Francisco, CA USA
[11] Genentech Inc, Biostat, San Francisco, CA USA
[12] F Hoffmann La Roche, Clin Sci, Basel, Switzerland
[13] F Hoffmann La Roche, Canc Immunotherapy Clin Safety, Basel, Switzerland
[14] Genentech Inc, Oncol Biomarker Dev, San Francisco, CA 94080 USA
[15] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
[16] Queen Mary Univ London, Barts Canc Inst, London, England
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.2244
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA16
引用
收藏
页码：S1148 / S1148
页数：1
相关论文
共 50 条
  • [31] Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
    Zefei Jiang
    Quchang Ouyang
    Tao Sun
    Qingyuan Zhang
    Yuee Teng
    Jiuwei Cui
    Haibo Wang
    Yongmei Yin
    Xiaojia Wang
    Xin Zhou
    Yongsheng Wang
    Gang Sun
    Jingfen Wang
    Lili Zhang
    Jin Yang
    Jun Qian
    Min Yan
    Xinlan Liu
    Tienan Yi
    Ying Cheng
    Man Li
    Aimin Zang
    Shusen Wang
    Chuan Wang
    Xinhong Wu
    Jing Cheng
    Hui Li
    Ying Lin
    Cuizhi Geng
    Kangsheng Gu
    Chunwei Xie
    Huihua Xiong
    Xiaohong Wu
    Junlan Yang
    Qingshan Li
    Yiding Chen
    Fanfan Li
    Anqin Zhang
    Yongqiang Zhang
    Yudong Wu
    Jianyun Nie
    Qiang Liu
    Kun Wang
    Xueli Mo
    Lilin Chen
    Yueyin Pan
    Peifen Fu
    Helong Zhang
    Danmei Pang
    Yuan Sheng
    Nature Medicine, 2024, 30 : 249 - 256
  • [32] Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study
    Arpino, Grazia
    De Placido, Sabino
    De Angelis, Carmine
    ANTI-CANCER DRUGS, 2015, 26 (01) : 117 - 122
  • [33] First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer A Cost-Effectiveness Analysis
    Weng, Xiuhua
    Huang, Xiaoting
    Li, Hongchao
    Lin, Shen
    Rao, Xin
    Guo, Xianzhong
    Huang, Pinfang
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (05): : 340 - 348
  • [34] Pilot study of carboplatin, nab-paclitaxel and pembrolizumab for metastatic triple-negative breast cancer
    Baar, Joseph
    Abraham, Jame
    Budd, G. Thomas
    Silverman, Paula
    Montero, Alberto
    Moore, Halle
    Fu, Pingfu
    Varadan, Vinay
    Ladaika, Kara
    Hricik, Lauren
    CANCER RESEARCH, 2021, 81 (04)
  • [35] Phase II study of sitravatinib plus tislelizumab with or without nab-paclitaxel in patients with locally recurrent or metastatic triple negative breast cancer
    Fan, Lei
    Liu, Xiyu
    Xu, Ying
    Sui, Xinyi
    Zhang, Wenjuan
    Ma, Linxiaoxi
    Jin, Xi
    Wu, Song-Yang
    Wang, Han
    Xiao, Yi
    Chen, Li
    Wu, Jiong
    Yu, Ke-da
    Liu, Guangyu
    Hu, Xin
    Wang, Zhonghua
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    CANCER RESEARCH, 2024, 84 (09)
  • [36] Cost-effectiveness of combined atezolizumab/nab-paclitaxel for advanced triple-negative breast cancer.
    Salans, Mia A.
    Cherry, Daniel R.
    Yip, Anthony T.
    Courtney, Patrick T.
    Kumar, Abhishek
    Murphy, James Don
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] IN SILICO VIRTUAL CLINICAL TRIALS OF ATEZOLIZUMAB AND NAB-PACLITAXEL IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER.
    Wang, H.
    Ma, H.
    Sove, R.
    Emens, L.
    Popel, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S23 - S23
  • [38] IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab plus carboplatin plus paclitaxel or nab-paclitaxel vs carboplatin plus nab-paclitaxel in 1L advanced squamous NSCLC
    Socinski, M. A.
    Rittmeyer, A.
    Shapovalov, D.
    Orlandi, F.
    McCleod, M.
    Soo, R. A.
    Palmero, R.
    Kozuki, T.
    Migliorino, M. R.
    Koynov, K. D.
    Berard, H.
    Hughes, B. G. M.
    Yu, W.
    Graupner, V.
    Sun, S. W.
    Kowanetz, M.
    Hoang, T.
    Lin, W.
    Jotte, R. M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [39] IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab plus carboplatin plus paclitaxel or nab-paclitaxel vs carboplatin plus nab-paclitaxel as 1L therapy in advanced squamous NSCLC.
    Jotte, Robert M.
    Cappuzzo, Federico
    Vynnychenko, Ihor
    Stroyakovskiy, Daniil
    Abreu, Delvys Rodriguez
    Hussein, Maen A.
    Soo, Ross A.
    Conter, Henry Jacob
    Kozuki, Toshiyuki
    Silva, Carlos
    Graupner, Vilma
    Sun, Shawn
    Lin, Ray S.
    Kelsch, Claudia
    Kowanetz, Marcin
    Tien Hoang
    Sandler, Alan
    Socinski, Mark A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)
  • [40] IMpassion130: Final OS Analysis From the Pivotal Phase III Study of Atezolizumab
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (11) : 9 - 11
12345